Biomednewsbreaks - Bioadaptives Inc. (BDPT) Announces Dividend For Common Stock Shareholders
Date
1/21/2025 11:06:55 PM
(MENAFN- Investor Brand Network)
BioAdaptives (OTC: BDPT) , a forward-thinking innovator in health and wellness solutions, today announced that FINRA has approved a dividend to its common stock shareholders. The decision reflects the company's gratitude for the unwavering support of its shareholders and their confidence in BioAdaptives' mission and growth trajectory.“This dividend is a heartfelt thank you to our shareholders who have stood by us through our journey,” said James Keener, CEO of BioAdaptives.“Your confidence in our vision to revolutionize health and wellness has been integral to our progress. This gesture underscores our appreciation and reaffirms our commitment to delivering long-term value as we advance our product portfolio and market reach.”
To view the full press release, visit
About BioAdaptives Inc.
BioAdaptives is a leading innovator in the health and wellness industry, dedicated to developing and marketing nutraceutical and wellness products that harness the power of natural ingredients and cutting-edge science. Its mission is to improve the quality of life for customers by offering products that support optimal health and vitality. For more information about Xcellara(TM) Stem Cell Activator and other BioAdaptives products, visit .
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: /Disclaimer
BioMedWire
Austin, Texas
512.354.7000 Office
[email protected]
BioMedWire is powered by IBN
MENAFN21012025000224011066ID1109115525
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.